Evidence map›Paper›PMID 26885640›Full record

ReviewAnnals of biomedical engineering2016

Multiscale Modeling in the Clinic: Drug Design and Development.

Colleen E Clancy, Gary An, William R Cannon, Yaling Liu, Elebeoba E May, Peter Ortoleva, Aleksander S Popel, James P Sluka, Jing Su, Paolo Vicini and 2 more

Abstract readReview
In one paragraph

Review in Annals of biomedical engineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Assessment of the Anti-adipogenic Effect ofCurrent pharmaceutical biotechnology · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Bioavailability by design - Vitamin DNanomedicine : nanotechnology, biology, and medicine · 2022
    Article
  11. Article
  12. Mechanisms of flecainide induced negative inotropy: An in silico study.Journal of molecular and cellular cardiology · 2021
    Article
  13. Article
  14. Organization of the Pluripotent Genome.Cold Spring Harbor perspectives in biology · 2021
    Review
  15. Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Colleen E ClancyDepartment of Pharmacology, University of California, Davis, CA, USA. ceclancy@ucdavis.edu.
Gary AnDepartment of Surgery, University of Chicago, Chicago, IL, USA.
William R CannonComputational Biology Group, Pacific Northwest National Laboratory, Richland, WA, USA.
Yaling LiuDepartment of Mechanical Engineering and Mechanics, Bioengineering Program, Lehigh University, Bethlehem, PA, USA.
Elebeoba E MayDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Peter OrtolevaDepartment of Chemistry, Indiana University, Bloomington, IN, USA.
Aleksander S PopelDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
James P SlukaBiocomplexity Institute, Indiana University, Bloomington, IN, USA.
Jing SuDepartment of Radiology, Wake Forest University, Winston-Salem, NC, USA.
Paolo ViciniClinical Pharmacology and DMPK, MedImmune, Cambridge, UK.
Xiaobo ZhouDepartment of Radiology, Wake Forest University, Winston-Salem, NC, USA.
David M EckmannDepartment of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, USA. eckmanndm@uphs.upenn.edu.
Indiana University Bloomington · USWake Forest University · USJohns Hopkins University · USLehigh University · USPacific Northwest National Laboratory · USUniversity of California, Davis · USUniversity of Chicago · USUniversity of Houston · USUniversity of Pennsylvania · US

Funding

ULTRASTRUCTURE AND CYTOMORPHOLOGY COREP30DK042086 · NIDDK · UNIVERSITY OF CHICAGO · PI LIU, CAMBRIAN YANGSHAO · 1990 to 2025
$29.8M
Predictive experiment-based multiscale models of the tumor immune microenvironment and immunotherapy in breast cancerR01CA138264 · NCI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2009 to 2023
$8.1M
In silico Safety PharmacologyR01HL128537 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E, SANTANA, LUIS F · 2016 to 2024
$5.7M
Development and Improvement of Tissue Simulation ToolkitR01GM077138 · NIGMS · TRUSTEES OF INDIANA UNIVERSITY · PI D'SOUZA, ROSHAN M, GLAZIER, JAMES ALEXANDER · 2007 to 2015
$4.0M
Predictive multiscale in silico cardio-pharmacologyU01HL126273 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E · 2015 to 2019
$3.8M
Targeted Microcarrier Design and OptimizationR01EB006818 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI ECKMANN, DAVID M · 2008 to 2016
$3.3M
Bridging multiple scales in modeling targeted drug nanocarrier deliveryU01EB016027 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI ECKMANN, DAVID M, RADHAKRISHNAN, RAVI · 2013 to 2017
$2.7M
Development of a Multiscale Mechanistic Simulation of Acetaminophen Induced LiverU01GM111243 · NIGMS · TRUSTEES OF INDIANA UNIVERSITY · PI DUNN, KENNETH W, GLAZIER, JAMES ALEXANDER · 2014 to 2017
$2.1M
Adaptive Simulation to Enable Anatomic-scale Agent-basedR01GM115839 · NIGMS · UNIVERSITY OF CHICAGO · PI AN, GARY, MACAL, CHARLES MARTIN · 2015 to 2017
$1.2M
An Integrated Biometric Platform for Evaluation of Nanomedicine DeliveryR15EB015105 · NIBIB · LEHIGH UNIVERSITY · PI LIU, YALING · 2013 to 2013
$443k
NCI NIH HHS R01 CA138264NHLBI NIH HHS R01 HL128537NHLBI NIH HHS U01 HL126273NIBIB NIH HHS R01 EB006818NIBIB NIH HHS R15 EB015105NIBIB NIH HHS U01 EB016027NIDDK NIH HHS P30 DK042086NIGMS NIH HHS R01 GM077138NIGMS NIH HHS R01 GM115839NIGMS NIH HHS U01 GM111243
6 · The paper itself

Abstract

A wide range of length and time scales are relevant to pharmacology, especially in drug development, drug design and drug delivery. Therefore, multiscale computational modeling and simulation methods and paradigms that advance the linkage of phenomena occurring at these multiple scales have become increasingly important. Multiscale approaches present in silico opportunities to advance laboratory research to bedside clinical applications in pharmaceuticals research. This is achievable through the capability of modeling to reveal phenomena occurring across multiple spatial and temporal scales, which are not otherwise readily accessible to experimentation. The resultant models, when validated, are capable of making testable predictions to guide drug design and delivery. In this review we describe the goals, methods, and opportunities of multiscale modeling in drug design and development. We demonstrate the impact of multiple scales of modeling in this field. We indicate the common mathematical and computational techniques employed for multiscale modeling approaches used in pharmacometric and systems pharmacology models in drug development and present several examples illustrating the current state-of-the-art models for (1) excitable systems and applications in cardiac disease; (2) stem cell driven complex biosystems; (3) nanoparticle delivery, with applications to angiogenesis and cancer therapy; (4) host-pathogen interactions and their use in metabolic disorders, inflammation and sepsis; and (5) computer-aided design of nanomedical systems. We conclude with a focus on barriers to successful clinical translation of drug development, drug design and drug delivery multiscale models.

Indexed as

Computer SimulationDrug DesignModels, TheoreticalAnimalsDrug Delivery SystemsHumansDrug deliveryMathematicalMultiscale modelingPharmacologySimulation

Identifiers

PMID26885640
PMCPMC4983472
OpenAlexW2287937249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.